Notably, in contrast to its consistent association with immunotherapeutic outcomes, TESC expression showed no significant relationship with treatment response in an independent cohort of patients with HCC receiving OXA-based chemotherapy alone, despite a nonsignificant trend toward higher TESC levels in nonresponders ( Supplemental Figure 1E ).
← all excerpts
Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma.
1
—
—